D Orazio & Associates Inc. Has $1.54 Million Stake in Johnson & Johnson (NYSE:JNJ)

D Orazio & Associates Inc. increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 54.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,267 shares of the company’s stock after acquiring an additional 3,262 shares during the period. D Orazio & Associates Inc.’s holdings in Johnson & Johnson were worth $1,537,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson in the fourth quarter valued at approximately $29,000. Conquis Financial LLC bought a new stake in Johnson & Johnson in the fourth quarter worth approximately $33,000. Bernard Wealth Management Corp. acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $36,000. Finally, Runnymede Capital Advisors Inc. bought a new position in shares of Johnson & Johnson during the 4th quarter valued at $38,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on JNJ. Wall Street Zen downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 22nd. Barclays reduced their target price on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a report on Thursday, April 17th. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Thursday, June 5th. Bank of America reduced their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, April 10th. Finally, Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Stock Up 0.2%

JNJ stock opened at $156.90 on Monday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market cap of $377.52 billion, a PE ratio of 23.59, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The business’s 50-day simple moving average is $153.84 and its 200 day simple moving average is $153.70.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a yield of 3.31%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.